Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
12 March 2020Next earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 21 Jun 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
ELVN Latest News
Enliven Therapeutics reached a 52-week high following the release of promising proof of concept data from an initial trial of its blood cancer treatment. The company shared results from a Phase 1 study of its drug ELVN-001 in CML patients who have not responded well to existing treatments.
BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will participate in a panel discussion at TD Cowen's 44th Annual Health Care Conference in Boston, MA, on Tuesday, March 5, 2024, at 12:50 p.m. ET.
Enliven Therapeutics, Inc. is a recently merged biopharma company focused on developing oncology candidates for leukemia and lymphoma. The company has raised $165 million in a private placement to fund its pipeline, which includes two phase 1 candidates. ELVN-001 targets chronic myeloid leukemia and shows promise in preclinical tests, while ELVN-002 is a selective HER2 inhibitor with potential in HER2-driven cancers.
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June:
What type of business is Enliven Therapeutics?
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
What sector is Enliven Therapeutics in?
Enliven Therapeutics is in the Healthcare sector
What industry is Enliven Therapeutics in?
Enliven Therapeutics is in the Biotechnology industry
What country is Enliven Therapeutics from?
Enliven Therapeutics is headquartered in United States
When did Enliven Therapeutics go public?
Enliven Therapeutics initial public offering (IPO) was on 12 March 2020
What is Enliven Therapeutics website?
https://www.enliventherapeutics.com
Is Enliven Therapeutics in the S&P 500?
No, Enliven Therapeutics is not included in the S&P 500 index
Is Enliven Therapeutics in the NASDAQ 100?
No, Enliven Therapeutics is not included in the NASDAQ 100 index
Is Enliven Therapeutics in the Dow Jones?
No, Enliven Therapeutics is not included in the Dow Jones index
When does Enliven Therapeutics report earnings?
The next expected earnings date for Enliven Therapeutics is 09 August 2024